OHC participated in the clinical trial titled, “A Single-Arm, Open-Label, Expanded Access Study of RO5185426 in Patients with Metastatic Melanoma.” The purpose of this clinical trial was to allow access to this study drug to patients in which... Read More

OHC participated in the clinical trial titled, “A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based... Read More